SANN — Santhera Pharmaceuticals Holding AG Share News
0.000.00%
Last trade - 00:00- CH₣220.90m
- CH₣220.41m
- CH₣77.19m
Brief: Santhera Launches Exchange Offer For CHF 60 Million Convertible Bonds
Swiss stocks - Factors to watch on March 19
Brief: Santhera Completes Capital Increase For Financing Arrangements
Brief: Santhera: Results Of Bondholders’ Meeting
Brief: Santhera Completes First 6-Month Period Of Pivotal Vision-DMD Trial With Vamorolone
Brief: Santhera Announces Positive Results With Lonodelestat
Brief: Santhera Calls EGM To Seek Approval For Strengthening Its Capital Structure
Brief: Santhera FY Net Loss Of CHF 71.2 Mln
Brief: Santhera Completes Capital Increase
Brief: Santhera Completes Capital Increase For Financing Arrangements
Europe Research Roundup: Legrand, Reckitt, Thales
Swiss stocks - Factors to watch on November 6
Brief: Santhera To Cut Jobs By 50%, Secures Financing For Vamorolone
Brief: Santhera Completes Capital Increase For Financing Arrangements
Santhera: Hits 3-yr low after cancels development of Puldysa in DMD
Europe Research Roundup: Andritz, Pendragon, Weir Group
Santhera: Partly de-risked, CS ups
Santhera halts trial of DMD drug Puldysa, launches revamp
Brief: Santhera To Discontinue Phase 3 Sideros Study And Focus On Vamorolone